The biggest story from the world's largest diabetes meeting was not a new scientific breakthrough. Instead, the lasting memory from the American Diabetes Association (ADA) 2017 Scientific Sessions will be the agonal breathing of the analog era of medicine.
Leaders of the ADA decided that the ideas, the facts, the science presented in San Diego must stay in San Diego, only later to be doled out in allotments and framing deemed acceptable to the $160-million-strong organization.